Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience

Executive Summary

• U.S. President Donald Trump issued an executive order reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act.
• The reclassification removes major research barriers, enabling expanded clinical trials and potentially increasing institutional investment in pharmaceutical‑grade cannabis companies such as MediPharm Labs.
• MediPharm Labs highlights its existing FDA site registration, Drug Establishment License, and experience supplying U.S. clinical trial material, positioning it to capture new research partnership opportunities.

Key Details

• The executive order “recognizes the medical use of cannabis” and is intended to accelerate marijuana‑related medical research in the United States.
• MediPharm Labs’ CEO David Pidduck called the order a “historic milestone” that validates the company’s pharmaceutical approach and will strengthen U.S. clinical trial partnerships.
• The President’s statement emphasizes the expected “tremendously positive impact” on medical research.
• Reclassification to Schedule III is anticipated to:
• Allow easier access to standardized, medical‑grade cannabis for researchers.
• Enable institutional investors previously restricted by “Schedule I trafficking” clauses to consider cannabis‑focused pharma companies.
• Potentially pave the way for federally sanctioned medical access programs similar to those in Canada, Australia and Germany.
• MediPharm Labs currently supplies product for over 10 active U.S. clinical trials, including a NIH‑funded Phase 2 study (LiBBY) that used API sourced from a Canadian Licensed Producer.
• The company’s regulatory credentials include:
• FDA site registration and Drug Establishment License (DEL).
• GMP/EU‑GMP certified operations and the first FDA‑audited purpose‑built commercial cannabis facility in Canada.
• Historical context: In 2023 MediPharm acquired VIVO Cannabis Inc., expanding its reach to medical patients in Canada, Australia, and Germany, and adding Harvest Medical Clinics to its portfolio.

Notable Quotes

“This reclassification order is a historic milestone that validates MediPharm's pharmaceutical approach and one that we anticipate will strengthen our ability to expand U.S. clinical trial partnerships.” – David Pidduck, CEO, MediPharm Labs

“It's going to have a tremendously positive impact.” – President Donald Trump

Materiality Assessment: Material – Positive** (the regulatory change is likely to materially affect the company’s growth prospects and investor interest).